Relapsed or Refractory Multiple Myeloma Clinical Trial
Official title:
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on the fourth-generation of CAR-T techonology.
Status | Recruiting |
Enrollment | 25 |
Est. completion date | April 2024 |
Est. primary completion date | October 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Patients with relapsed/refractory multiple myeloma aged 18-75 years; 2. BCMA expression =50% in bone marrow samples confirmed by Flow Cytometry or IHC is positive for BCMA expression; 3. Relapsed/refractory patients who meet the following conditions: 1. Ineffective or disease progression after receiving bortezomib (proteasome inhibitor) and lenalidomide for 3 courses; 2. Ineffective or disease progression after receiving the original treatment plan for 3 courses; 3. The interval between the last treatment and disease progression is more than 30 days; 4. There is currently no indication for hematopoietic stem cell transplantation, or the patient refuses to do hematopoietic stem cell transplantation; 5. The definition of disease progression refers to the "2014 IMWG Standards", and at least meets the following 1 items: e.1 Serum M protein = 0.5 g/dL; e.2 Urine M protein = 200 mg/24 h; e.3 If the serum FLC ratio is abnormal, the patient's FLC level = 10 mg/dL (100 mg/L); e.4 Evaluable plasmacytoma confirmed by biopsy; e.5 Increase in the proportion of bone marrow plasma cells =25% (absolute increase =10%); e.6 Bone marrow plasma cells account for 30% of the total bone marrow cells; 4. Estimated survival time> 12 weeks; 5. The disease status can be assessed and meet at least one of the following: 1. Serum M-protein =10 g/L; 2. 24h urine M-protein =200mg; 3. Serum FLC=5mg/dL; 4. Plasma cell tumors that can be assessed by testing or images; 5. The proportion of bone marrow plasma cells = 30%; 6. ECOG physical status score 0-1; 7. Have enough venous access for apheresis or venous blood collection, and there are no other contraindications for blood cell separation; 8. WBC = 1.5×109/L; PLT = 45×109/L; 9. Serum creatinine = 1.5 upper limit of normal (ULN) ; 10. ALT = 2.5 ULN, AST = 2.5 ULN. All laboratory test results within the above range should have no ongoing continuous supportive treatment. Exclusion Criteria: - Subjects who meet any of the following criteria cannot be selected for this study: 1. Systemic treatment such as lymphatic depletion with cyclophosphamide and fludarabine within 2 weeks before enrollment or single cell collection, or cell therapy within 8 weeks before treatment; 2. HCV or HIV positive; any uncontrollable active infection, including active tuberculosis, HBV DNA level =1×103 copies/mL; 3. Active infections occurred within 72 hours before cleansing; as long as there is no evidence of active infection and antibiotics are not in the list of prohibited drugs, subjects who continue to use preventive antibiotics, antifungal drugs or antiviral drugs are not excluded; 4. The current systemic use of cyclosporine or steroid drugs such as dexamethasone, recent or current use of inhaled steroids is not excluded; 5. Renal insufficiency, serum creatinine>1.5 upper limit of normal (ULN); 6. Liver insufficiency, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)>2.5 times ULN and direct bilirubin>1.5 times ULN; 7. Hyponatremia, blood sodium <125 mmol/L; 8. Baseline serum potassium <3.5 mmol/L (potassium supplementation can be given before participating in the study, and serum potassium recovery above this standard is not excluded); 9. Pregnant or lactating women; 10. Other serious diseases that may restrict subjects from participating in this trial (such as central nervous system disease, severe heart insufficiency, myocardial obstruction or unstable arrhythmia or unstable angina, gastric ulcer in the past 6 months , Active autoimmune diseases, etc.). |
Country | Name | City | State |
---|---|---|---|
China | 2nd Affiliated Hospital, School of Medicine, Zhejiang University | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Second Affiliated Hospital, School of Medicine, Zhejiang University | Carbiogene Therapeutics Co. Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of grade 3 or 4 treatment related adverse effect | All the CAR-T treatment related adverse events,including Dose limiting toxicity (DLT), cytokine release syndrome (CRS), CAR-T associated encephalopathy syndrome, will be assessed and graded by NCI CTCAE v 5.0. | 24 weeks after last dose of CAR-T treatment | |
Primary | Overall response rate (ORR) after treated by CAR-T treatment | ORR will be assessed and graded by the international Myeloma Working Group (IMWG) Unified response criteria for multiple myeloma | up to 2 years after CAR-T treatment | |
Secondary | Pharmacokinetics of CAR-T cells (implantation endpoint) | To assess the duration of CAR-positive T cells in circulation, the copy number of CAR DNA was measured at the preset follow-up time point. The time when the results of any two consecutive tests were negative, were recorded as the "implantation endpoint". | up to 2 years after CAR-T treatment | |
Secondary | Overall survival | From date of inclusion to date of progression, relapse, or death from any cause. | up to 2 years after CAR-T treatment | |
Secondary | Progression free survival | The length of time that a participant's disease did not progress during and after CAR-T treatment. | up to 2 years after CAR-T treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03837509 -
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05519085 -
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
|
Phase 3 | |
Active, not recruiting |
NCT02099539 -
QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT00545519 -
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05052970 -
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
|
Phase 1 | |
Completed |
NCT03464916 -
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
|
Phase 1 | |
Recruiting |
NCT05455320 -
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
|
Phase 3 | |
Withdrawn |
NCT05408026 -
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04684108 -
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
|
Phase 1 | |
Recruiting |
NCT05652335 -
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
|
Phase 1 | |
Completed |
NCT03859427 -
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01866293 -
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06375044 -
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT01058434 -
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
|
Phase 2 | |
Recruiting |
NCT04735575 -
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06298266 -
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
|
Early Phase 1 | |
Recruiting |
NCT05572515 -
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
|
Phase 3 | |
Active, not recruiting |
NCT04798586 -
MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
|
Phase 1 | |
Terminated |
NCT02075021 -
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
Completed |
NCT00478777 -
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
|
Phase 3 |